细胞免疫治疗在急性白血病中的临床应用进展

Application advances in cellular immunotherapy for acute leukemia

急性白血病（AL）是最常见的血液系统恶性肿瘤，基于化疗药物的开发应用和化疗方案的不断改进，AL诱导化疗后缓解率得到明显提高，但缓解后复发仍是白血病患者不能长期生存的主要原因，如何延长治疗后缓解期成为解决此问题的关键。细胞免疫治疗在消除白血病微小残留病（MRD）、降低白血病复发、提高白血病患者总生存（OS）率方面有重要作用，细胞免疫治疗越来越受到人们的重视。就细胞免疫疗法在AL中的临床应用进展作一综述。

Acute leukemia is the most common hematological malignancies. Based on the development of chemotherapy drugs and the improvement of chemotherapy regimens,the remission rate after induction chemotherapy increases obviously. But leukemia patients can not live for a long time mainly because of the ease relapse , so how to extend remission after treatment become the key to solve the problem. People are paying more and more attention on the cellular immunotherapy since it playes major roles in eradicating minimal residual disease of leukemia ,reducing leukemia relapse and improving leukemia patients overall survival. This article reviews the application advances in research on this subject.